Indium-111-labeled girentuximab immunoSPECT as a diagnostic tool in clear cell renal cell carcinoma

European Urology

Volumn 63, Issue 6, 2013, Pages 1101-1106

  Muselaers, Constantijn H J ^a   Boerman, Otto C ^a   Oosterwijk, Egbert ^a   Langenhuijsen, Johannes F ^a   Oyen, Wim J G ^a   Mulders, Peter F A ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

CAIX; Chimeric monoclonal antibody G250; Clear cell renal cell carcinoma; Girentuximab; Renal masses

Indexed keywords

CARBONATE DEHYDRATASE IX; GIRENTUXIMAB; INDIUM 111;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; DRUG UPTAKE; FEMALE; HUMAN; IMAGE ANALYSIS; IMMUNOSPECT; INCIDENTALOMA; INJECTION; ISOTOPE LABELING; KIDNEY CARCINOMA; KIDNEY TUMOR; MALE; METASTASIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SYSTEMIC THERAPY; TUMOR VOLUME; WHOLE BODY SCINTISCANNING;

AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIGENS, NEOPLASM; CARBONIC ANHYDRASES; CARCINOMA, RENAL CELL; FEMALE; HUMANS; INDIUM RADIOISOTOPES; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; RADIOPHARMACEUTICALS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TUMOR MARKERS, BIOLOGICAL;

EID: 84876492367     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2013.02.022     Document Type: Article

References (23)

1. T. Lebret, J.E. Poulain, and V. Molinie Percutaneous core biopsy for renal masses: indications, accuracy and results J Urol 178 2007 1184 1188 discussion 1188
2. A. Volpe, K. Mattar, and A. Finelli Contemporary results of percutaneous biopsy of 100 small renal masses: a single center experience J Urol 180 2008 2333 2337
3. H.Y. Wang, H.J. Ding, and J.H. Chen Meta-analysis of the diagnostic performance of [18F]FDG-PET and PET/CT in renal cell carcinoma Cancer Imaging 12 2012 464 474
4. M.H. Bui, D. Seligson, and K.R. Han Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy Clin Cancer Res 9 2003 802 811
5. B.C. Leibovich, Y. Sheinin, and C.M. Lohse Carbonic anhydrase IX is not an independent predictor of outcome for patients with clear cell renal cell carcinoma J Clin Oncol 25 2007 4757 4764
6. E. Oosterwijk, D.J. Ruiter, and P.J. Hoedemaeker Monoclonal antibody G 250 recognizes a determinant present in renal-cell carcinoma and absent from normal kidney Int J Cancer 38 1986 489 494
7. J. Pastorek, S. Pastorekova, and I. Callebaut Cloning and characterization of MN, a human tumor-associated protein with a domain homologous to carbonic anhydrase and a putative helix-loop-helix DNA binding segment Oncogene 9 1994 2877 2888
8. R. Opavsky, S. Pastorekova, and V. Zelnik Human MN/CA9 gene, a novel member of the carbonic anhydrase family: structure and exon to protein domain relationships Genomics 33 1996 480 487
9. J.E. Surfus, J.A. Hank, and E. Oosterwijk Anti-renal-cell carcinoma chimeric antibody G250 facilitates antibody-dependent cellular cytotoxicity with in vitro and in vivo interleukin-2-activated effectors J Immunother Emphasis Tumor Immunol 19 1996 184 191
10. A.H. Brouwers, W.C. Buijs, and E. Oosterwijk Targeting of metastatic renal cell carcinoma with the chimeric monoclonal antibody G250 labeled with (131)I or (111)In: an intrapatient comparison Clin Cancer Res 9 2003 3953S 3960S
11. E. Oosterwijk, N.H. Bander, and C.R. Divgi Antibody localization in human renal cell carcinoma: a phase I study of monoclonal antibody G250 J Clin Oncol 11 1993 738 750
12. M.G. Steffens, O.C. Boerman, and J.C. Oosterwijk-Wakka Targeting of renal cell carcinoma with iodine-131-labeled chimeric monoclonal antibody G250 J Clin Oncol 15 1997 1529 1537
13. A.H. Brouwers, P.F. Mulders, and P.H. de Mulder Lack of efficacy of two consecutive treatments of radioimmunotherapy with 131I-cG250 in patients with metastasized clear cell renal cell carcinoma J Clin Oncol 23 2005 6540 6548
14. C.R. Divgi, N.H. Bander, and A.M. Scott Phase I/II radioimmunotherapy trial with iodine-131-labeled monoclonal antibody G250 in metastatic renal cell carcinoma Clin Cancer Res 4 1998 2729 2739
15. C.R. Divgi, J.A. O'Donoghue, and S. Welt Phase I clinical trial with fractionated radioimmunotherapy using 131I-labeled chimeric G250 in metastatic renal cancer J Nucl Med 45 2004 1412 1421
16. C.R. Divgi, N. Pandit-Taskar, and A.A. Jungbluth Preoperative characterisation of clear-cell renal carcinoma using iodine-124-labelled antibody chimeric G250 (124I-cG250) and PET in patients with renal masses: a phase I trial Lancet Oncol 8 2007 304 310
17. Stillebroer AB, Boerman OC, Desar IME, et al. Phase 1 radioimmunotherapy study with lutetium 177-labeled anti-carbonic anhydrase IX monoclonal antibody girentuximab in patients with advanced renal cell carcinoma. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2012.08.024.
18. A.H. Brouwers, J.E. van Eerd, and C. Frielink Optimization of radioimmunotherapy of renal cell carcinoma: labeling of monoclonal antibody cG250 with 131I, 90Y, 177Lu, or 186Re J Nucl Med 45 2004 327 337
19. National Institutes of Health Clinical Center. The effect of sorafenib (Nexavar) on 111-indium labeled chimeric monoclonal antibody G250 or 111-indium labeled bevacizumab (Avastin) uptake in patients with clear cell RCC (ccRCC). NCT00602862. ClinicalTrials.gov Web site. http://clinicaltrials.gov/show/ NCT00602862. Updated February 22, 2012.
20. C.R. Divgi, R.G. Uzzo, and C. Gatsonis Positron emission tomography/computed tomography identification of clear cell renal cell carcinoma: results from the REDECT Trial J Clin Oncol 31 2013 187 194
21. I.M. Desar, A.B. Stillebroer, and E. Oosterwijk 111In-bevacizumab imaging of renal cell cancer and evaluation of neoadjuvant treatment with the vascular endothelial growth factor receptor inhibitor sorafenib J Nucl Med 51 2010 1707 1715
22. C.H.J. Muselaers, A.B. Stillebroer, and M.J. Boers-Sonderen Sorafenib reduces the tumor uptake of Indium-111-girentuximab in clear cell renal cell carcinoma patients Eur J Nucl Med Mol Imaging 39 Suppl 2 2012 S188 S189
23. National Institutes of Health Clinical Center. Pilot trial to evaluate the utility of 124I-cG250 for the early detection of response to therapy in patients with metastatic renal cell carcinoma. NCT01582204. ClinicalTrials.gov Web site. http://clinicaltrials.gov/ct2/show/NCT01582204?term= NCT01582204&rank=1. Updated December 17, 2012.